Skip to main content
Premium Trial:

Request an Annual Quote

Medison to Market CardioDx's Corus CAD in Israel

NEW YORK (GenomeWeb News) – Medison will make available CardioDx's Corus CAD diagnostic test for obstructive coronary artery disease in Israel as part of an agreement announced today.

Under the terms of the deal, Medison will market and sell Corus CAD in Israel, where heart disease is the second-leading cause of death and responsible for 16 percent of all deaths annually, the companies said. Blood samples from patients in Israel will be shipped to CardioDx's CLIA-certified laboratory in Palo Alto, Calif., for analysis and test reporting.

Financial and other terms of the deal were not disclosed.

Corus CAD is a gene expression test for assessing obstructive CAD in non-diabetic patients. CardioDx said it is the only sex-specific test for diagnosing obstructive CAD "that accounts for critical biological differences between men and women," to help physicians in the early determination of potential obstructive CAD.

A recent study published in the Journal of the American Board of Family Medicine found that Corus CAD had a significant impact on decisions by doctors in the primary care setting and changed their treatment strategies, as Pharmacogenomics Reporter reported.

In October, CardioDx filed with the US Securities and Exchange Commission to go public. With its shares anticipated to fetch between $14 and $16 per share, its planned initial public offering is expected to raise about $92 million, the firm said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.